ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
Dow Jones
38.852,27
0,46%
Euro vs US Dollar
1,07713
0,04%
Bitcoin
63.597,26
0,68%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Athersys Inc (ATHX)

  7. Athersys Inc (ATHX) News

ATHX

Athersys (ATHX)

Athersys Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ATHX
DatumZeitQuelleÜberschriftSymbolFirma
08/01/202413h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
22/12/202323h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
21/12/202317h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATHXAthersys Inc
16/11/202314h35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATHXAthersys Inc
18/10/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
16/10/202322h52Business WireAthersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic AlternativesNASDAQ:ATHXAthersys Inc
12/10/202315h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
11/10/202315h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
10/10/202314h30Business WireAthersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with HealiosNASDAQ:ATHXAthersys Inc
06/10/202323h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATHXAthersys Inc
06/10/202323h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATHXAthersys Inc
03/10/202322h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
03/10/202322h30Business WireAthersys Licenses its Animal Health Assets to Ardent Animal HealthNASDAQ:ATHXAthersys Inc
02/10/202323h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
02/10/202323h04Business WireAthersys Director Jane Wasman Appointed Board ChairNASDAQ:ATHXAthersys Inc
25/09/202322h36Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATHXAthersys Inc
22/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATHXAthersys Inc
19/09/202318h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATHXAthersys Inc
19/09/202303h35Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ATHXAthersys Inc
19/09/202303h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
14/09/202317h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATHXAthersys Inc
14/09/202316h41Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATHXAthersys Inc
13/09/202323h13Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATHXAthersys Inc
11/09/202314h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
06/09/202320h45Business WireGrant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney TransplantationNASDAQ:ATHXAthersys Inc
21/08/202320h36Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ATHXAthersys Inc
18/08/202316h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHXAthersys Inc
18/08/202303h30Business WireAthersys, Inc. Announces Pricing of $3.5 Million Public OfferingNASDAQ:ATHXAthersys Inc
17/08/202322h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ATHXAthersys Inc
16/08/202323h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATHXAthersys Inc
 Showing the most relevant articles for your search:NASDAQ:ATHX

Kürzlich von Ihnen besucht

AMEX
SPY
SPDR S&P 500
CCOM
US30
US 30
NASDAQ
MSFT
Microsoft
USOTC
ADDYY
Adidas (QX)
USOTC
RHHBY
Roche (QX)
TG
432
Arbor Metals
AMEX
XLE
Energy Select Sector SPDR
TG
DTE
Deutsche Telekom
TG
BAYN
Bayer
TG
NOV
Novo Nordisk
AMEX
XLV
Health Care Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US500
US 500
COIN
SOLUSD
Solana
DBI
TDXP
Tec DAX
DBI
MDAX
MDAX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten